Skip to search formSkip to main contentSkip to account menu

Keam Breast Cancer 2013 Oncology Response Criteria

Known as: KEAM BREAST CANCER 2013 
Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. (Keam B, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N… 
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 5201: Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: Therapeutic implications for immune checkpoint inhibitors
Background: We aimed to compare intra- and extracranial responses to immune checkpoint inhibitors (ICIs) in lung cancer with… 
2017
2017
Abstract 3157: Osimertinib (AZD9291) is effective against NSCLC cells harboringEGFRexon 20 insertion mutations
Background: Although EGFR exon 20 insertion mutation is the third most common among EGFR-mutant NSCLC, this mutant clones are… 
2017
2017
Abstract 652: PD-L1 and MHC class 1 expression levels are modulated by MEK inhibition on head and neck squamous cell carcinoma
Background: To overcome immunosuppression, multiple pathways can be targeted by counter strategies, including elimination of… 
2015
2015
Abstract 2416: Activity of sunitinib for lung adenocarcinoma with RET rearrangement
Background Oncogenic driver gene rearrangement involving RET proto-oncogene has been observed in about 1% of non-small-cell lung… 
2015
2015
Abstract 4946: Investigating candidate genomic alteration which affects the local recurrence in patients with desmoid fibromatosis
BACKGROUND Desmoid tumor (DT) is known as a locally aggressive tumor caused by altered Wnt/b-catenin signaling pathway. Although… 
2014
2014
Abstract 1842: Synergistic inhibition of ALK inhibitor-resistant lung cancer cells by dual-targetingEGFRandALKpathways
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Despite the excellent initial responses of ALK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)